Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population

BACKGROUND: Cystic fibrosis (CF) is a rare, life-threatening disease that results in severe respiratory, digestive, and metabolic problems. Elexacaftor/tezacaftor/ivacaftor is an oral drug that was approved by the US Food and Drug Administration (FDA) on October 21, 2019, after demonstrating clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Spenser, Borchardt, Molly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372948/
https://www.ncbi.nlm.nih.gov/pubmed/35737861
http://dx.doi.org/10.18553/jmcp.2022.28.7.721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372948/
https://www.ncbi.nlm.nih.gov/pubmed/35737861
http://dx.doi.org/10.18553/jmcp.2022.28.7.721

Ejemplares similares